![](/imgs/covers/cr_cover.jpg)
|
Journal of Cancer Research and Therapeutics
Medknow Publications on behalf of the Association of Radiation Oncologists of India (AROI)
ISSN: 0973-1482 EISSN: 0973-1482
Vol. 6, No. 3, 2010, pp. 313-315
|
Bioline Code: cr10071
Full paper language: English
Document type: Case Report
Document available free of charge
|
|
Journal of Cancer Research and Therapeutics, Vol. 6, No. 3, 2010, pp. 313-315
en |
Crystalline maculopathy: A rare complication of tamoxifen therapy
Srikantia, Nirmala; Mukesh, S. & Krishnaswamy, Malavika
Abstract
Tamoxifen is a selective estrogen receptor modulator widely used in the treatment of hormone-responsive breast cancer. Tamoxifen-induced ocular complications are very rare. A post-menopausal woman, diagnosed and treated case of carcinoma of left breast, on follow-up presented with history of gradual diminution of vision in both eyes of 3 months duration. Patient was on tamoxifen therapy 20 mg daily for the last 2 years. Fundus examination showed crystalline maculopathy. Fluorescein angiography, ocular coherence tomography confirmed the diagnosis. Tamoxifen therapy was discontinued. Although ocular toxicity is rare, careful evaluation of patients with visual symptoms on tamoxifen therapy is required.
Keywords
Breast cancer, crystalline maculopathy, ocular toxicity, tomoxifen therapy
|
|
© Copyright 2010 Journal of Cancer Research and Therapeutics. Alternative site location: http://www.cancerjournal.net/
|
|